- Previous Close
1.2400 - Open
1.2800 - Bid --
- Ask --
- Day's Range
1.1200 - 1.2800 - 52 Week Range
0.8500 - 4.4000 - Volume
6,683 - Avg. Volume
36,110 - Market Cap (intraday)
30.443M - Beta (5Y Monthly) 0.90
- PE Ratio (TTM)
-- - EPS (TTM)
-2.5800 - Earnings Date Apr 1, 2025 - Apr 3, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities. The company also develops PASylated-nomacopan, which is in preclinical development for the treatment of geographic atrophy secondary to dry age-related macular degeneration; and hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) combined with nomacopan, which is in phase 3 clinical development for the treatment of pediatric HSCT-TMA. The company is headquartered in Boston, Massachusetts.
www.akaritx.comRecent News: AKTX
View MorePerformance Overview: AKTX
Trailing total returns as of 4/1/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AKTX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AKTX
View MoreValuation Measures
Market Cap
32.83M
Enterprise Value
31.58M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-20.16M
Diluted EPS (ttm)
-2.5800
Balance Sheet and Cash Flow
Total Cash (mrq)
2.25M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--